Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
|
|
AIDS (09.26.03) Vol. 17; No. 14: P.2121-2124 - Tuesday, December 30, 2003
Mardge H. Cohen; Yolanda Olszewski; Bernard Branson; Michele Robey; Faridah Love; Denise J. Jamieson; Marc Bulterys; for the Mother Infant Rapid Intervention At Delivery Study
All four hospitals are participants in the Mother Infant Rapid Intervention At Delivery Study. MIRIAD is a multisite study funded by CDC to: determine the feasibility of rapid HIV testing in obstetric units among women with undocumented HIV status; to provide timely therapy to reduce perinatal transmission; and to facilitate follow-up care for HIV- infected mothers and infants.
Hospital staff who performed the test in labor and delivery clipped timers to their clothing so they could continue other work during the 20 minutes it took for test results to develop. In the hospital where testing was done in the laboratory, nurses brought specimens to the laboratory and reported results to patients once they came back from the laboratory.
The researchers found that the median turnaround time between testing and results at point-of-care hospitals was 45 minutes compared to more than 3.5 hours at the hospital where rapid tests were taken to the lab. "Point-of-care testing was feasible and accurate, permitting undiagnosed HIV-infected pregnant women to learn their HIV status quickly, and access intrapartum antiretroviral therapy to reduce vertical transmission," the authors concluded.
031230
AD032694
Copyright © 2003 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.